tbuckley/cabot-search huggingface dataset:
TMIC-34. SENESCENT ASTROCYTE INDUCED INFLAMMATION MAY UNDERLIE SEX DIFFERENCES IN THE AGE-DEPENDENT RISE IN GLIOBLASTOMA INCIDENCE
Authors: Gina Rhee, Lauren Broestl, Lucia Grandison, Nicole Warrington, Najla Kfoury, Jasmin Sponagel, Cameron Hill, Joshua Rubin
Journal: Neuro-Oncology (2019)

Abstract Sex differences in the rates of glioblastoma increase with age. There are likely to be multiple biological mechanisms underlying these sex differences. Here, we focused on the changes that occur with aging in the secretomes of male and female astrocytes to determine whether sex differences in chemokine and cytokine secretion, and inflammatory cell recruitment, could be one of those mechanisms. We focused on glioblastoma (GBM) and the role that senescent astrocytes might play in the age-dependent widening of the gap between male and female GBM cases. We found that the senescence associated secretory phenotype of male and female astrocytes significantly differed, notably in the enrichment of Fractalkine (1.33:1 (F:M)), the primary chemoattractant for microglia, in female compared to male SASP. This was in contrast to the greater abundance of tumorigenic growth factors like bFGF (1.25:1 (M:F)), in the male SASP. Implantation of either male or female senescent astrocytes into the brains of mice resulted in the recruitment of microglia to the injection site. Regardless of the recipient mouse sex, female astrocyte implantation resulted in significantly larger microglial infiltrates (2-fold) and greater astrocyte activation, as compared to the injection of equal numbers of male senescent cells. We propose a model for how sex differences in astrocyte SASP could result in lower rates of GBM with age in females: greater microglial attraction to senescent cells results in their enhanced clearance and consequently a reduction in senescence-associated GBM promotion.
Inhibition of TLR4 Signaling Affects Mitochondrial Fitness Overcoming Bortezomib Resistance in Myeloma Plasma Cells
Authors: Cesarina Giallongo, Daniele Tibullo, Giuseppina Camiolo, Fabrizio Puglisi, Daniela Cambria, Alessandro Barbato, Nunziatina Laura Parrinello, Alessandra Romano, Concetta Conticello, Angela Amorini, Giovanni Li Volti, Giuseppe Lazzarino, Giuseppe A. Palumbo, Francesco Di Raimondo
Journal: Blood (2019)
Rational Modification of Intestinal Microbiome and Metabolites after Allogeneic Hematopoietic Stem Cell Transplantation with Resistant Starch: A Pilot Study
Authors: Mary Mansour Riwes, Alexander Schmidt, Thomas Braun, John M. Magenau, Attaphol Pawarode, Brian Parkin, Sarah Anand, Monalisa Ghosh, John Maciejewski, Darren King, Muneesh Tewari, Sung W. Choi, Gregory A. Yanik, Kristi Maccready, Thomas Schmidt, Pavan Reddy
Journal: Blood (2019)
EARLY STAGE Follicular Lymphoma: First Results of the FIL "Miro" Study, a Multicenter Phase II Trial Combining Local Radiotherapy and MRD-Driven Immunotherapy
Authors: Alessandro Pulsoni, Maria Elena Tosti, Simone Ferrero, Stefano Luminari, Anna Marina Liberati, Natalia Cenfra, Daniela Renzi, Emanuela Zanni, Carola Boccomini, Andres JM Ferreri, Sara Rattotti, Vittorio Ruggero Zilioli, Patrizia Bernuzzi, Silvia Bolis, Gerardo Musuraca, Luca Nassi, Tommasina Perrone, Caterina Stelitano, Antonella Anastasia, Paolo Corradini, Giovanni Partesotti, Francesca Re, Emanuele Cencini, Clara Mannarella, Donato Mannina, Anna Lia Molinari, Monica Tani, Giorgia Annechini, Giovanni Manfredi Assanto, Lavinia Grapulin, Irene Della Starza, Marzia Cavalli, Lucia Anna De Novi, Elena Ciabatti, Barbara Mantoan, Anna Guarini, Luca Arcaini, Umberto Ricardi, Valter Gattei, Sara Galimberti, Marco Ladetto, Ilaria Del Giudice, Robin Foà
Journal: Blood (2019)
Harnessing the Epichaperome As a Therapeutic Approach in Multiple Myeloma
Authors: Eloisi Caldas Lopes, Tai Wang, David S Jayabalan, Tony Taldone, Jorge Monge, Jorge Contreras, Yip Winnie, Vicenta Trujillo, Panchal Palak, Nicholas Lombardi, Sharma Sahil, Digwal Chander, Morton Coleman, Gabriela Chiosis, Ruben Niesvizky, Monica L. Guzman
Journal: Blood (2019)
Renal Vein Thrombosis in Infants
Authors: Louis A. Vega
Journal: JAMA (1961)

RENAL VEIN thrombosis is a condition that appears mostly in the first weeks of life, usually as a complication of severe diarrhea and dehydration, 1 characterized by gross hematuria, albuminuria, oliguria, azotemia, and, usually, a palpable abdominal mass.  It was pointed out by Barenberg 2 in 1941 that the physicians of the nineteenth century regarded renal vein thrombosis a common occurrence in young infants. However, most of the recent reports on this condition consider the diagnosis rarely made clinically. McClelland and Hughes 3 in 1950 reported only three cases from a review of 328 autopsies in infants. Kobernick, Moore, and Wiglesworth 4 in 1951 reported on four cases found among 1,092 autopsies in infants over a period of 12 years.  It appears that Campbell and Matthews 5 were the first to make the clinical diagnosis of this condition in this country in 1941. Apparently, up to 1956 only a
Metal-captured inhibition of pre-mRNA processing activity by CPSF3 controls <i>Cryptosporidium</i> infection
Authors: Christopher Swale, Alexandre Bougdour, Audrey Gnahoui-David, Julie Tottey, Sonia Georgeault, Fabrice Laurent, Andrés Palencia, Mohamed-Ali Hakimi
Journal: Science Translational Medicine (2019)

Targeting parasitic endonuclease CPSF3 with an oxaborole offers a potent and selective candidate treatment against cryptosporidiosis.
ACTR-26. SAFETY AND EFFICACY OF BEVACIZUMAB PLUS TTFIELDS IN PATIENTS WITH RECURRENT GLIOBLASTOMA (GBM): DATA FROM A PHASE II CLINICAL TRIAL
Authors: Jaleh Fallah, Rekha Chaudhary, Lisa Rogers, Wei (Auston) Wei, Cathy Brewer, David Peereboom, Manmeet Ahluwalia
Journal: Neuro-Oncology (2019)

Abstract BACKGROUND Studies of bevacizumab monotherapy and TTFields monotherapy have shown activity but limited clinical benefit in patients with recurrent GBM. In an open label, single-arm, phase 2 clinical trial, the safety and efficacy of the combination of bevacizumab and TTFields was studied in patients with recurrent GBM. METHOD Bevacizumab-naïve patients with histologically confirmed GBM or other grade IV glioma, with recurrent disease after radiotherapy and temozolomide chemotherapy, were eligible. Bevacizumab dose was 10mg/kg intravenously every 2 weeks and TTFields was worn at least 18 hours daily. The primary endpoint was safety, progression-free survival at 6 months (PFS6) and overall survival at 12 months (OS12). Treatment was continued until disease progression or unacceptable toxicity. Survival outcomes were assessed using the Kaplan-Meier method. Treatment-related adverse events were reported according to CTCAE, v4.0 criteria. RESULTS 25 patients were enrolled and 23 were eligible for data analysis: 18 (78%) men and 5 (22%) women, median age 60 years (range 17–78). 21 patients were Caucasian, 1 was African American and 1 of unknown race. Median follow-up was 6.0 months (range 2.4–22). Seven patients (30 %) had disease progression. Median PFS was 9.9 (95% CI: 6.7-NA) months. PFS rate at 6 months (PFS6) was 71% (95% CI: 0.54–0.94). Median overall survival was 9.9 (95%CI 7.3-NA) months. OS rate at 12 months (OS12) was 42% (95%CI 0.24–0.74). 7 patients (30%) had grade 3 toxicity (cough, dysphagia, muscle weakness, hyperglycemia, hypertension, psychosis, seizure, lymphopenia, transaminitis). 1 patient developed grade 4 muscle weakness in the lower extremities. CONCLUSION Treatment with the combination of bevacizumab and TTFields in patients with recurrent GBM is safe and feasible and has shown clinical efficacy.
EXTH-06. DOWN-REGULATION OF PD-L1 VIA FKBP5 LOWERED BY A CYCLOOXYGENASE-2 INHIBITOR IN GSCs AND GBM CELLS MAY BE ATTRIBUTABLE TO ENHANCE ANTITUMOR EFFECTS OF IMMUNOTHERAPY
Authors: Izumi Yamaguchi, Kohei Nakajima, Kenji Shono, Yoshifumi Mizobuchi, Toshitaka Fujihara, Keiko Kitazato, Yasushi Takagi
Journal: Neuro-Oncology (2019)

Abstract BACKGROUND Antitumor therapies targeting programmed cell death-1 (PD-1)/its ligand-1 (PD-L1) are influential at present stage. However, in glioblastoma (GBM), the expression of PD-L1 is variable and the role of anti-PD-1 antibody therapy is still unclear. The high expression of PD-L1 affects cell proliferation and invasion in GBM cells. As COX-2 modulates PD-L1 expression in cancer cells, we tested our hypothesis that a COX-2 inhibitor, celecoxib may play a role on anti-PD-1 antibody treatment via down-regulation of PD-L1. METHODS Six weeks old male C57BL/6 mice subjected to intracranial injection of mice glioma stem cells (GSCs) were randomly divided into four treatment groups; vehicle control (VC), celecoxib, anti PD-1 antibody or the combination of celecoxib and anti-PD-1 antibody groups and examined antitumor effects. To verify the mechanisms underlying antitumor effects, mice GSCs and human GBM cells were used. RESULTS Compared to each single treatment in the glioma model, the combination therapy of anti PD-1 antibody and celecoxib significantly decreased the tumor volume and improved the survival period. Importantly, the high expression of PD-L1 in the glioma model, mice GSCs and human GBM cells was decreased by celecoxib. Interestingly, the reduction of PD-L1 was associated with post-transcriptional regulation of co-chaperone FK506-binding protein 5 (FKBP5) by celecoxib. The combination therapy of anti PD-1 antibody with celecoxib could be a promising therapeutic strategy targeting PD-L1 in GSCs and GBM. CONCLUSIONS Down-regulation of PD-L1 via FKBP5 by celecoxib may play a role on the antitumor effects under the overwhelmed expression of PD-L1.
Validation of Daraex to Resolve Daratumumab-Induced Interferences in Pre-Transfusion Screen Tests
Authors: Maria Tenorio, Gemma Moreno Jiménez, Valentín García Gutiérrez, Ana Jiménez, Maria Jesús Blanchard, Ana Vallés, Sandra López, Pilar Herrera, Javier Lopez Jimenez, Anabelle Chinea
Journal: Blood (2019)
Is there an optimal irradiation dose for photodynamic therapy: 37 J cm <sup>−2</sup> or 75 J cm <sup>−2</sup> ?
Authors: B.K. Todd, A. Lesar, P. O'Mahoney, E. Eadie, S.H. Ibbotson
Journal: British Journal of Dermatology (2019)

Topical photodynamic therapy (PDT) is widely used for the treatment of Bowen's disease (BD) and superficial basal cell carcinoma (BCC).The process involves oxygen-dependent light activation of the tissue-localised photosensitiser, protoporphyrin IX, three hours after pro-drug application to the lesion.Current approved and licensed regimens involve application of either methylaminolevulinate (MAL, Metvix, Galderma, Switzerland) or 5-aminolaevulinic acid in nanocolloid emulsion (ALA, Ameluz gel, Biofrontera, Germany) and subsequent light activation using narrow spectrum (630-635 nm) red light (typically light emitting diodes (LEDs)), at an unweighted radiant exposure ("dose") of 37 Jcm -2 (1-3).
Markers of Initial and Long-Term Responses to Idecabtagene Vicleucel (Ide-Cel; bb2121) in the CRB-401 Study in Relapsed/Refractory Multiple Myeloma
Authors: Ethan G. Thompson, Yue Jiang, Timothy B. Campbell, Jaymes Fuller, Shari Kaiser, Afshin Mashadi-Hossein, Julie Rytlewski, Nathan Martin, Olivia Finney, Katja Kleinsteuber, Eric Alonzo, Chetanya Pandya, Amit Agarwal, Kristen Hege, Noopur S. Raje, Nikhil C. Munshi, Ronald J. Hause
Journal: Blood (2019)
Anti-BTN3A 20.1 Agonist Monoclonal Antibody Enhances Autologous Vγ9Vδ2 T Cells Cytotoxicity Against Primary Acute Myeloid Blasts
Authors: Anne-Charlotte Le Floch, Florence Orlanducci, Antoine Briantais, Aude Le Roy, Anne-Sophie Chretien, Norbert Vey, Daniel Olive
Journal: Blood (2019)
Study of Diagnosis, Classification and Prognostic Factors Determination of Acute Leukemia By Flow Cytometry Immunophenotyping
Authors: Alessandra Suelen Jardim Silva, Juliana Mendonça Freire, Lenilton Silva DA Silva Júnior, Gustavo Henrique de Medeiros Oliveira, Antonia Eduarda Martins Oliveira Elói Silva, João Pedro Andrade Lima, Victor lima Soares, Rodrigo Villar Freitas, Frank Bahia, Taissa Moura Oliveira, Dany GKC Silva, Valéria SF Sales, Rafael Santiago Araujo, Hugo Diogenes De Oliveira Paiva, Aldair Sousa Paiva, Geraldo Barroso Cavalcanti
Journal: Blood (2019)
P1.25 Rare Intimal Aortic Angiosarcoma Diagnosed via Endobronchial Ultrasound guided Transbronchial Fine Needle Aspiration (EBUS-TBNA): A Case Report
Authors: L. Fernandez-Trujillo, D.C. Buenaventura, E.I. Morales, J.E. Garcia, L. Sua
Journal: Journal of Thoracic Oncology (2019)
Identifying a Simple Clinical Prognostic Model for Aggressive Adult T-Cell Leukemia/Lymphoma in Latin American Population and Its Validation: A Large International Study of the Latin America Working Group for Lymphomas (GELL)
Authors: Luis E Malpica Castillo, Camila Peña, Christine Rojas, Pilar León, Brady E. Beltrán, Denisse A. Castro, Yesenia M. Huerta- Collado, Mimsy Quinones, Sally Rose Paredes, Henry Idrobo, Ivan Perdomo, Virginia Abello, Lorena Fiad, Victoria Otero, Marialejandra Torres Viera, Luis Villela M, Eduardo Sotomayor, Jorge J Castillo, Juan Carlos Ramos
Journal: Blood (2019)
Clinical Response in Relapsed/Refractory (R/R) B-NHL Treated with the CD19-Directed CAR T-Cell Product JWCAR029
Authors: Zhitao Ying, Pengpeng Xu, Li Wang, Shu Cheng, Wen Wu, Wen Wang, Ming Hao, Su Yang, Harry Lam, James Li, Hongxia Zheng, Weili Zhao, Yuqin Song, Jun Zhu
Journal: Blood (2019)
P2.25 Immunotherapy at Any Line of Treatment Improves Survival in Hispanic Patients with Advanced Metastatic Non-Small Cell Lung Cancer (NSCLC) Compared with Chemotherapy (Quijote-CLICaP)
Authors: A.F. Cardona, A. Ruiz-Patiño, O. Arrieta, C. Martín, L. Raez, L. Zatarain Barron, F. Barrón, L. Ricaurte, M.A. Bravo-Garzón, L. Mas, L. Corrales-Rodriguez, L. Rojas, L. Lupinacci, F. Perazzo, C. Bas, O. Carranza, C. Pupareli, M. Rizzo, R. Ruiz Mendoza, C.D. Rolfo, P. Archila, J. Rodríguez, C. Sotelo, C. Vargas, H. Carranza, J. Otero, L.E. Pino, C. Ortíz, P. Laguado, R. Rosell
Journal: Journal of Thoracic Oncology (2019)
School-based interventions to prevent anxiety and depression in children and young people: a systematic review and network meta-analysis
Authors: Deborah M Caldwell, Sarah R Davies, Sarah E Hetrick, Jennifer C Palmer, Paola Caro, José A López-López, David Gunnell, Judi Kidger, James Thomas, Clare French, Emily Stockings, Rona Campbell, Nicky J Welton
Journal: The Lancet Psychiatry (2019)

Rates of anxiety and depression are increasing among children and young people. Recent policies have focused on primary prevention of mental disorders in children and young people, with schools at the forefront of implementation. There is limited information for the comparative effectiveness of the multiple interventions available.
Gene Editing ELANE in Human Hematopoietic Stem and Progenitor Cells Reveals Disease Mechanisms and Therapeutic Strategies for Severe Congenital Neutropenia
Authors: Shuquan Rao, Josias Brito-Frazao, Anna V. Serbin, Qiuming Yao, Kevin Luk, Yuxuan Wu, Jing Zeng, Chunyan Ren, Ruth Watkinson, Myriam Armant, Luca Pinello, Akiko Shimamura, Benhur Lee, Scot A. Wolfe, Peter E. Newburger, Daniel E. Bauer
Journal: Blood (2019)
IMPACT-TB*: A Phase II Trial Assessing the Capacity of Low Dose Imatinib to Induce Myelopoiesis and Enhance Host Anti-Microbial Immunity Against Tuberculosis. *Imatinib Mesylate per Oral As a Clinical Therapeutic for TB
Authors: Cynthia R. Giver, Pamela A Shaw, Helen Fletcher, Deepak Kaushal, Garcia Pamela, Deborah Omoyege, Gregory Bisson, Tawanda Gumbo, Robert Wallis, Edmund K. Waller, Daniel Kalman
Journal: Blood (2019)
Commonly Studied Single-Nucleotide Polymorphisms and Breast Cancer: Results From the Breast Cancer Association Consortium
Journal: JNCI Journal of the National Cancer Institute (2006)

Abstract Background: The Breast Cancer Association Consortium (BCAC) is an international collaboration that was established to provide large sample sizes for examining genetic associations. We conducted combined analyses on all single-nucleotide polymorphisms (SNPs) whose associations with breast cancer have been investigated by at least three participating groups. Methods: Data from up to 12 studies were pooled for each SNP ( ADH1C I350V, AURKA F31I, BRCA2 N372H, CASP8 D302H, ERCC2 D312N, IGFBP3 −202 c &gt; a , LIG4 D501D, PGR V660L, SOD2 V16A, TGFB1 L10P, TP53 R72P, XRCC1 R399Q, XRCC2 R188H, XRCC3 T241M, XRCC3 5′ UTR, and XRCC3 IVS7-14). Genotype frequencies in case and control subjects were compared, and genotype-specific odds ratios for the risk of breast cancer in heterozygotes and homozygotes for the rare allele compared with homozygotes for the common allele were estimated with logistic regression. Statistical tests were two-sided. Results: The total number of subjects for analysis of each SNP ranged from 12 013 to 31 595. For five SNPs— CASP8 D302H, IGFBP3 −202 c &gt; a , PGR V660L, SOD2 V16A, and TGFB1 L10P—the associations with breast cancer were of borderline statistical significance ( P = .016, .060, .047, .056, and .0088 respectively). The remaining 11 SNPs were not associated with breast cancer risk; genotype-specific odds ratios were close to unity. There was some evidence for between-study heterogeneity ( P &lt;.05) for four of the 11 SNPs ( ADH1C I350V, ERCC2 D312N, XRCC1 R399Q, and XRCC3 IVS5-14). Conclusion: Pooling data within a large consortium has helped to clarify associations of SNPs with breast cancer. In the future, consortia such as the BCAC will be important in the analysis of rare polymorphisms and gene × gene or gene × environment interactions, for which individual studies have low power to identify associations, and in the validation of associations identified from genome-wide association studies.
Mode of delivery and survival in babies weighing less than 2000 g at birth
Authors: J S. Crawford
Journal: BMJ (1981)

not helped by the above measures or for patients in whom the fourth sacral root is menaced.This approach bascd on painstaking attention to applied anatomy, clinical observa- tion, and, in 'the case of epidural local anaesthesia, simple good luck has provided a rational and effective way of dealing with this common problem.This contrasts strongly with the muddle which passes for rational treatment throughout the United Kingdom.The "orthodox" treatments consist of:(1) Useless treatments: heat (and now ultraviolet light), massage, and exercises.Where is the evidence for their effectiveness ?(2) "Correct" treatments done wrongly.Traction given intermittently or only once or twice a week.Manipulation done under anaesthesia-how does the manipulator know he has produced an effective manoeuvre?Epidurals using the wrong local anaesthetic in too small a volume via the wrong route.(3) "Correct" treatments given for the wrong lesion.Traction for hard or irreducible displacements.Manipulation for soft lesions.Epidurals for reducible lesions.Laminectomy for lesions which would respond to con- servative treatment.( 4) Everything (manipulation, traction, epidurals, not forgetting heat and exercises) for all cases of sciatica.
Investigations on Novel Gene Variants Associated with Longterm Response to Tyrosine Kinase Inhibitors (TKIs) in Chronic Myeloid Leukemia: Implication in TKI-Cessation Clinical Trails
Authors: Zafar Iqbal, Muhammad Absar, Abid Jameel, Tanveer Akhtar, Sulman Basit, Aamer Mahmood, Aamir Aleem, Nawaf Alanazi, Ullah Anhar, Naila Batool Khalid, Sibtain Afzal, Jamil Amjad Hashmi, Afia M Akram, Khushnooda Ramzan, Mahmood Rasool, Muhammad Hasaan Aziz, Muhammad Farooq Sabar, Mudassar Iqbal, Ahmad Mukhtar Khalid
Journal: Blood (2019)
18F-NaF Uptake in Retroperitoneal Neurofibroma and Uterine Leiomyoma Calcifications
Authors: Huipan Liu, Yue Chen, Ling Yang, Wenhui Fu
Journal: Clinical Nuclear Medicine (2019)

Abstract A 48-year-old woman with intermittent lower back pain for 9 months and known retroperitoneal neurofibroma underwent 18 F-NaF PET/CT scan to assess possible bony lesions causing the pain. Incidentally, the images showed elevated NaF activity in the retroperitoneal neurofibroma. In addition, uterine leiomyoma with heterogeneous calcifications revealed increased NaF activity.
Results from the Completed Hgb-205 Trial of Lentiglobin for β-Thalassemia and Lentiglobin for Sickle Cell Disease Gene Therapy
Authors: Elisa Magrin, Michaela Semeraro, Alessandra Magnani, Hervé Puy, Annarita Miccio, Nicolas Hebert, Jean-Sebastien Diana, Francois Lefrere, Felipe Suarez, Olivier Hermine, Valentine Brousse, Catherine Poirot, Philippe Bourget, Wassim El Nemer, Isabelle Guichard, Despina Moshous, Benedicte Neven, Fabrice Monpoux, Marilyne Poirée, Pablo Bartolucci, Jean-François Meritet, David Grévent, Thibaud Lefebvre, Mohammed Asmal, Erin Whitney, Marisa Gayron, Wenmei Huang, Isabelle Funck-Brentano, Mariane de Montalembert, Laure Joseph, Jean-Antoine Ribeil, Marina Cavazzana
Journal: Blood (2019)
Favorable Progression-Free Survival Associated with Immune Bio-Markers Modulated By Pomalidomide in Relapsed/Refractory Multiple Myeloma: An Analysis of Phase III Study
Authors: Rao Prabhala, Mehmet Kemal Samur, Srikanth Talluri, Megan Stekla, Chaitanya Yenumula, Michael A Lopez, Sanika Derebail, Lakshmi B. Potluri, Angela Wang, Aishwarya Katiki, Sahan D. Vangala, Eric Haas, Michael J Buonopane, Alexander T Heubeck, Mariateresa Fulciniti, Raphael Szalat, Suzan Lazo-Kallanian, Kevin Hong, Teresa Peluso, John Daley, Tsvetan Biyukov, Albert Oriol, William E. Pierceall, Paul G. Richardson, Kenneth C. Anderson, Anjan Thakurta, Hervé Avet-Loiseau, Nikhil C. Munshi
Journal: Blood (2019)
Cytogenetic subclone formation and evolution in progressive smoldering multiple myeloma
Authors: Maximilian Merz, Thomas Hielscher, David Schult, Elias K. Mai, Marc S. Raab, Jens Hillengass, Anja Seckinger, Dirk Hose, Martin Granzow, Anna Jauch, Hartmut Goldschmidt
Journal: Leukemia (2019)
THE TREATMENT OF PERNICIOUS ANEMIA
Authors: C F Borchgrevink
Journal: JAMA (1926)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Durvalumab-induced Organizing Pneumonia with a Diffuse Micronodular Pattern in a Patient with Lung Cancer
Authors: Masahiro Yamasaki, Masaya Taniwaki, Kazuma Kawamoto, Naoko Matsumoto, Kaori Hashimoto, Shinji Nabeshima, Nobuyuki Ohashi, Noboru Hattori
Journal: American Journal of Respiratory and Critical Care Medicine (2019)
Easix for Prediction of Survival in Myelodysplastic Syndromes
Authors: Almuth Maria Anni Merz, Ulrich Germing, Guido Kobbe, Jennifer Kaivers, Anna Jauch, Aleksandar Radujkovic, Manuela Hummel, Axel Benner, Maximilian Merz, Peter Dreger, Thomas Luft
Journal: Blood (2019)
Short-Term Noncryopreserved Hematopoietic Stem Cells: Single Center Experience of Autologous Transplantation
Authors: Sergei Voloshin, Andrey Garifullin, Anastasiya Kuzyaeva, Vasily Shuvaev, Alexander Schmidt, Alexey Kuvshinov, Valentina Balashova, Zhanna Chubukina, Elena Belyakova, Georgiy Rysev, Alexander Chechetkin, Viktor Rugal'
Journal: Blood (2019)